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Abstract
This study describes the development of simple, rapid and sensitive liquid chromatography tan-
dem mass spectrometry method for the simultaneous analysis of doxorubicin and its major
metabolite, doxorubicinol, in mouse plasma, urine and tissues. The calibration curves were linear
over the range 5–250 ng/mL for doxorubicin and 1.25–25 ng/mL for doxorubicinol in plasma and
tumor, over the range 25–500 ng/mL for doxorubicin and 1.25–25 ng/mL for doxorubicinol in
liver and kidney, and over the range 25–1000 ng/mL for doxorubicin and doxorubicinol in urine.
The study was validated, using quality control samples prepared in all different matrices, for accu-
racy, precision, linearity, selectivity, lower limit of quantification and recovery in accordance with
the US Food & Drug Administration guidelines. The method was successfully applied in determin-
ing the pharmaco‐distribution of doxorubicin and doxorubicinol after intravenously administra-
tion in tumor‐bearing mice of drug, free or nano‐formulated in ferritin nanoparticles or in
liposomes. Obtained results demonstrate an effective different distribution and doxorubicin pro-
tection against metabolism linked to nano‐formulation. This method, thanks to its validation in
plasma and urine, could be a powerful tool for pharmaceutical research and therapeutic drug
monitoring, which is a clinical approach currently used in the optimization of oncologic
treatments.
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1 | INTRODUCTION
Doxorubicin (DOX), an anthracycline glycoside antibiotic, is an excep-
tionally good antineoplastic agent and is widely used in the treatment
of various cancers, including lung, ovarian and breast cancer and malig-
nant lymphoma (Duggan & Keating, 2011Q2 ). However, long‐term clinical
use is limited due to the development of a progressive dose‐dependent
cardiomyopathy that irreversibly evolves toward congestive heart fail-
ure (Ho, Fan, Jou, Wu, & Sun, 2012). The current thinking is that DOX
is toxic per se but gains further cardiotoxicity after one‐electron reduc-
tion with reactive oxygen species overproduction or two‐electron
reduction with conversion to a secondary alcohol metabolite
doxorubicinol (DOXol). It became clear that is essential to quantify this
toxic metabolite of DOX in as much biomatrices as possible to study its
distribution in the organism after drug administration to understand
better the side effect mechanisms linked to DOX treatment. Further-
more, the antitumor activity of the drug was noticeably enhanced
when it was nano‐formulated. Indeed, DOX has been found to be more
effective in mice when loaded in nano‐drug delivery systems such as
polymeric nanoparticles, liposomes and bionanoparticles. Moreover
nano‐formulation protects DOX from undesired metabolism reducing
the formation of toxic derivatives as DOXol (Lianga et al., 2014; Park
et al., 2009). Actually, it is well‐known that nano‐formulation improves
drug bioavailability, delivery and accumulation to the tumor site. At the
Abbreviations used: CS, calibration standard; %CV, percentage coefficient of
variance; DAU, daunorubicin hydrochloride; DOX, doxorubicin; DOXol,
doxorubicinol; HQC, high quality control; LLE, liquid–liquid extraction; LOD,
limits of detection; LOQ, limits of quantification; LQC, low quality control;
MQC, medium quality control; QC, quality control; %RSE, percentage relative
standard error.
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same time, the tumor targeting of the drug implies the reduction of
organ‐sensitive toxicity because of the better tissue biodistribution.
Moreover, slow drug release from a storage structure help to enhance
the therapeutic index and reduce side effects (Rao et al., 2015).
Although the mechanisms by which targeted drugs are more efficient
is becoming increasingly clear, only few details about less toxicity asso-
ciated to nanoparticle‐loaded DOX than the free drug are available.
Information about the biodistribution of DOX delivered by nanoparti-
cles and, in particular, that of its cardiotoxic metabolite DOXol should
lead to a better understanding of the mechanisms related to reduced
nano‐formulated drug toxicity. Various analytical methods in which
detection limits, adequate to analyze plasma or serum from patients
receiving conventional chemotherapeutic treatments, have been
reported. The reported methods have mostly used HPLC coupled with
fluorescence (Zhou & Chowbay, 2002Q3 ), electrochemical (Ricciarello
et al., 1998) and chemiluminescence detection (Ahmed et al., 2009).
Moreover, apart from some published LC–MS/MS‐based methods
with validated quantifications of DOX and/or DOXol in some biologi-
cal matrices (Sottani, Poggi, Melchiorre, Montagna, & Minoia, 2013),
human plasma (Ibsen et al., 2013), tumors from mice (Liu, Yang, Liu,
& Jiang, 2008), rat plasma (Lachâtrea et al., 2000), human serum, less
attention was paid so far for analysis of DOX and its 13‐hydroxy
metabolite in mouse tissue samples suitable to study the tissue distri-
bution profile of nanoparticle‐delivered DOX (Arnold, Slack, &
Straubinger, 2004; Cao & Bae, 2012Q4 ; Park et al., 2006). In the present
study, a simple, fast and inexpensive HPLC method with MS–MS
detection has been developed and validated for quantification of
DOX and DOXol in mice biomatrices to obtain a powerful tool for drug
distribution evaluation in pharmaceutical research. The method was
applied to investigate in BALB/c tumor‐bearing mice the bioavailability
and biodistribution of DOX, differently formulated, and its reduced
metabolite, DOXol. We aimed to study the contribution of different
kinds of nano‐formulation to improve DOX bioavailability and
biodistribution in a murine in vivo tumor model. Moreover, the method
can also be applied in therapeutic drug monitoring, a clinical approach
used in the optimization of oncologic treatments.
2 | MATERIALS AND METHODS
2.1 | Materials
DOX hydrochloride and the internal standard daunorubicin hydrochlo-
ride (DAU) were purchased from Sigma (St. Louis, MO, USA). DOXol
trifluoroacetate salt was obtained from AlsaChim (Bioparc, Illkirch,
France). The HPLC grade solvents were purchased from Sigma.
2.2 | Control plasma, urine and mouse tissues
collection
Control human plasma and urine samples used for purification and
extraction studies and for validation experiments were obtained from
healthy volunteers. Blood was collected into a vial containing K+‐
EDTA, which was immediately centrifuged. Aliquots of 15mL of
pooled plasma were stored at −80°C. Human urine, obtained from
volunteer colleagues, was collected after a circadian cycle and aliquots
of 15mL of pooled urine were stored at −80°C.
Kidney and liver tissues used for purification and extraction
studies and for validation experiments were obtained from healthy
BALB/c mice.
The tumor tissue samples used in this study have been obtained
from an orthotopic model of murine breast cancer. The tumors were
generated by injecting in to the mammary fat pad of 8‐week‐old
BALB/c females 1 × 105 4 T1‐Luc cells (Bioware‐Ultra 4 T1‐Luc2 cell
line; PerkinElmer Q5). 4 T1‐Luc is a murine cell line stably transfected with
luciferase, which generates a very aggressive breast cancer. The
tumors were allowed to grow for 10 days, at which time they reached
a size of approximately 0.8 cm3. Mice were killed and organs were
explanted, weighted, transferred in a polypropylene plastic Eppendorf
tubes, immediately frozen by liquid nitrogen immersion and stored at
−80°C. Before extraction, whole organs were homogenized in water
(10% w/v) with potter Q6(Glas‐Col homogenizer) and divided in aliquots
of 200 μL.
2.3 | Preparation of standard solutions, calibration
standards and quality control samples
Stock solutions of DOX and DOXol were separately prepared in meth-
anol at a concentration of 1mg/mL from powder. Even DAU (internal
standard) stock solution was prepared in methanol from powder at
concentration of 1mg/mL. Three working solutions containing the
mixture of DOX and DOXol at concentrations of 10 μg/mL, 1 μg/mL
and 100 ng/mL, were prepared in methanol mixing and diluting first
stock solutions at 1mg/mL. Similarly, the DAU working solution was
prepared in methanol at a concentration of 100 ng/mL by diluting
the first stock solution. Aliquots of first stock solutions and second
stock solutions were stored at −80°C while the aliquot in use was
stored at −20°C.
Calibration standard (CS) samples were prepared in plasma, liver,
kidney and tumor tissue homogenates (0.2mL of homogenate 10%
w/v in water) by adding different volumes of the second stock solu-
tions of mixed DOX and DOXol to reach final concentrations of 1.25,
2.5, 5, 10, 25, 50, 100, 250 and 500 ng/mL. Each solution was spiked
with DAU internal standard solution (DAU 1 μg/mL, and 100 ng/mL
final concentration). CS for DOX and DOXol quantification in urine
samples were prepared in 0.1mL of human urine by adding different
volumes of the second stock solutions of mixed DOX and DOXol to
reach final concentrations of 25, 50, 100, 250, 500, 750 and
1000 ng/mL. Each solution was spiked with DAU as previously
described for other biomatrices.
Quality control (QC) samples were prepared in plasma, liver, kid-
ney and tumor tissue homogenates (0.2mL of homogenate 10% w/v
in water). Each sample was spiked with different volumes of the sec-
ond stock solutions of mixed DOX and DOXol at low (LQC), medium
(MQC) and high (HQC) concentration levels (5, 25 and 100 ng/mL for
DOX and 1.25, 5 and 25 ng/mL for DOXol) and with the second stock
solution of DAU. QC samples for validation in urine (0.1mL) were pre-
pared spiking different volumes of second stock solutions of mixed
DOX and DOXol at LQC, MQC and HQC concentration levels (50,
250 and 750 ng/mL) and a second stock solution of DAU.
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Pooled plasma or urine used for validation experiments were
prepared combining 30 different samples derived from healthy
volunteers.
All CS and QC samplesQ7 were extracted as described below and
immediately injected or stored at −80°C until the injection.
Liquid–liquid extraction (LLE) methods commonly used for drug
extractions from human plasma or tissue have been assessed. LLE
were performed in 15mL glass tubes. Different aqueous solutions
in combination with different organic phases have been tested.
Aqueous solutions were sodium borate solution (pH 9), acetate
buffer (pH 5), KOH 1M and H2SO4 1mM whereas the organic solu-
tions were acetonitrile/methyl alcohol 70: 30, chloroform/isopropyl
alcohol 50: 50, hexane/ethyl acetate 50: 50, hexane/ethyl acetate
90: 10, chloroform/heptane/isopropyl alcohol 50: 33: 17, dichloro-
methane/isopropyl alcohol 80: 20 and chloroform/acetone 50: 50.
In addition, homogenization of solid tissues directly in acetonitrile/
methyl alcohol 70: 30 has been tested. Comparing all the extrac-
tion methods that were tested, the combination of H2SO4 and
chloroform/isopropyl alcohol, as the organic phase, gave better
extraction yields. Consequently, CS and real samples were
extracted in the following way: 50 μL of plasma, or 25 μL of urine
or 200 μL of tissue homogenates (10% in water w/v), spiked with
DAU, diluted to 1mL with H2SO4 1mM and extracted with chloro-
form/isopropyl alcohol 50: 50. After organic phase evaporation, the
residual was dissolved in 50 μL of the initial mobile phase (water/
acetonitrile, 95: 5 v/v) and 20 μL were injected in to the HPLC
for analysis.
2.4 | HPLC–MS/MS analysis
The LC system was composed by a Dionex Ultimate 3000 Rapid Sep-
aration LC system (DionexThermo Fischer, Rodano Milanese, Italy).
Mass analyses were performed on a ABSciex 4000 Q‐trap LC–MS/
MS system (AB Sciex, Foster City, CA, USA). Ionization of analytes
was performed using electrospray ionization in a positive mode; the
ion source temperature was 550°C, ion spray voltage was 5500 V
and declustering potential was 62 V for DOX, DOXol and DAU. Direct
infusion and flow injection analysis of DOX, DOXol and DAU made it
possible to optimize the MS parameters for fragmentation in a multiple
reaction monitoring mode.
Separation of the analytes was carried out on a Phenomenex
Gemini C18 column (150mm× 2mm ID 3) at a flow rate of
0.350mL/min. Mobile phase A was ammonium formate 10mM, daily
prepared by means of a Milli‐Q Synthesis A10 System (Millipore,
Billerica, MA, USA), containing 0.1% v/v formic acid and mobile phase
B was acetonitrile. Several gradients of mobile phase A and B have
been tested for the chromatographic separation and the following
gradient has been selected: 0.0–1.0min 5% B; 1.0–3.0min to 90% B;
3.0–5.0min to 95% B; 5.0–6.0min 95% B; 6.0–6.1min to 5% B; and
6.1–8.5min 5% B. The retention times obtained in a total run of
8.5min, comprising re‐equilibration at 5% B, are listed in TableT1 1. A
representative HPLC–MS/MS analysis of a mouse plasma sample is
reported in FigureF1 1. Quantifications were performed using Multiquant
1.2.1 software by AB Sciex.
2.5 | Validation
The analytical method was validated to meet the acceptance criteria of
the US Food & Drug Administration guidelines Q8(US Department of
Health and Human Services, Food and Drug Administration, Center
for Drug Evaluation and Research, CDER, 2001). Important parameters
such as linearity, accuracy, precision, sensitivity (limits of detection
[LODs] and limits of quantification [LOQs]), specificity, recovery, sta-
bility and influence of matrix effects were determined using plasma,
urine and tissue samples.
2.6 | Selectivity, carry‐over and sensitivity
To exclude any interference or false positive response derived from
extractive procedure, reagents or disposable, blank water was
extracted according to the method Q9and analyzed in triplicate.
The carry‐over was evaluated by analyzing a solvent sample
(water/acetonitrile 95: 5 v/v) just after the highest CS. The signal–
noise ratio of the eventual DOX or DOXol peak in the solvent sample
was <2.5.
Sensitivity of the method was expressed by LOD and LOQ calcu-
lated on calibration curves prepared in plasma, urine, liver, kidney and
tumor tissue. LOD and LOQ are expressed respectively as 3.3 and 10
times the ratio between the standard deviation of the response and
the slope of the calibration curve (equations 1 and 2). The LOD and
LOQ values calculated for all biomatrices are reported in Table T22.
LOD ¼ 3:3 × SDav slope
Av slope
(1)
LOQ ¼ 10× SDav slope
Av slope
(2)
2.7 | Linearity, precision and accuracy
The linearity response of analytes was assessed on the five different
biomatrices over their respective calibration range from three batches
of analytical runs. Different calibration ranges for DOX and DOXol and
for different biomatrices have been chosen in relation to
TABLE 1 Multiple reaction monitoring transitions (m/z values), CE
(eV) and RT (min) used to identify and quantify analytes
Compound Mass Precursor Product CE RT
Doxorubicin 543.52 544.2 397.5a 19 4.49
361.5a 24
355.5 24
130.0 38
Doxorubicinol 545.54 546.2 399.5a 21 4.43
363.5a 35
130.0 30
Daunorubicin
hydrochloride
527.52 528.2 363.5a 21 4.54
321.5 21
CE, collision energy; RT, retention times.
aProduct ions used for quantification.
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concentrations expected in real samples. CS were prepared in plasma,
urine and tissues and extracted in triplicate as described. Twenty
microliters of eluates were injected and analyzed. A linear model was
used to describe the relationship between analyte concentration and
instrument response (analyte peak area/internal standard peak area)
and determination and variation coefficients (r2 and CV) were calcu-
lated (TableT3 3).
Precision and accuracy were determined by QC analyses at LQC,
MQC and HQC concentrations over three batch runs. For each QC,
analysis was performed in six replicates on each day. Precision was cal-
culated using equation 3 and is denoted by percentage coefficient of
variance (%CV). Accuracy was calculated using equation 4, where nom-
inal means theoretical amounts, and is denoted by a percentage rela-
tive standard error (%RSE). The accuracy and precision were required
to be within ±15% RSE of the nominal concentration and ≤15% CV
(Table T44).
%CV ¼ SD
Mean
 
×100 (3)
%RSE ¼ Mean−nonomin al
nonomin al
 
×100 (4)
2.8 | Recovery and matrix effect
To evaluate absolute recovery two sets of samples were prepared in
plasma, urine and tissue samples. The pre‐extraction spiked QC
FIGURE 1 Q17HPLC‐MS/MS spectra of a real sample of mouse plasma: chromatographic separation and MS/MS analysis of DOX, DOXol and DAU.
DAU, daunorubicin hydrochloride; DOX, doxorubicin; DOXol, doxorubicinol; MRM, multiple reaction monitoring (mode)
TABLE 2 Limit of the assay: LOD (expressed in ng/mL) and LOQ (expressed in ng/mL). Recovery expressed as percentage and matrix effect
expressed as percentage of ion suppression
DOX DOXol
Matrix effect Recovery Matrix effect Recovery
LOD LOQ LQC HQC LQC MQC HQC LOD LOQ LQC HQC LQC MQC HQC
Plasma 0.04 0.15 3 8 75 96 65 0.24 0.82 12 25 59 68 64
Liver 0.12 0.42 37 21 60 93 88 0.30 1.02 13 30 47 66 72
Kidney 0.43 1.48 25 38 73 86 90 0.32 1.05 32 28 66 73 85
Tumor 0.52 1.73 37 23 58 63 70 0.35 1.17 19 26 63 62 78
Urine 0.025 0.08 1 3 82 68 83 0.09 0.32 12 10 70 72 82
DOX, doxorubicin; DOXol, doxorubicinol; HQC, high quality control; LOD, limit of detection; LOQ, limit of quantification; LQC, low quality control; MQC,
medium quality control.
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samples (test samples) were prepared as described at low (DOX 5 ng/
mL; DOXol 1.25 ng/mL), medium (DOX 25 ng/mL; DOXol 5 ng/mL)
and high (DOX 100 ng/mL; DOXol 25 ng/mL) concentration levels for
all matrices except for urine where low, medium and high concentra-
tions were 50, 250 and 750 ng/mL for both DOX and DOXol. For
the post‐extraction spiked samples (reference samples), aliquots of
blank matrices (plasma/urine/liver/kidney/tumor tissue) were proc-
essed using the extraction method to yield post‐extraction superna-
tant. Pooled aliquots of post‐extraction supernatant were then
spiked using DOX and DOXol stock solutions to yield post‐extraction
samples containing DOX and DOXol at 5–25 and 100 ng/mL and
1.25–5 and 25 ng/mL respectively Q10(50, 250 and 750 ng/mL for both
DOX and DOXol for urine). All samples were analyzed sixfold and ana-
lyte recovery was determined at each concentration level using the
equation 5 where the ratio of the analyte peak areas of the test and
reference samples were expressed as a percentage recovery (%RE).
The average %RE was determined and the calculated precision (CV)
did not exceed 15%.
RE ¼ Peak area of test sample
Peak area of reference sample
 
×100 (5)
The presence of suppression or enhancement of the analytical sig-
nal was investigated using the post‐extraction spike method. Three
samples of pooled plasma, urines, liver, kidney and tumor tissue and
blank water were extracted following the proposed method. The stan-
dards were added to 50 μL of eluate at two concentration levels LQC
and HQC (5–250 ng/mL for different matrices and 25–750 ng/mL for
urine for DOX, and 1.25–25 ng/mL for different matrices and
25–750 ng/mL for urine for DOXol). Mean peak areas of standards
spiked in eluate from water (Aw) and from biomatrices (Ap) obtained
for each concentration were used for calculations (equation 6) and
results are reported as the ion suppression percentage (Table 2).
Matrix effect% ¼ 1− Ap
Aw
 
×100 (6)
2.9 | Sample stability
Stock solutions stability was established by quantification of samples
from dilution of two stock solutions stored at −80°C for 1month and
at room temperature for 6 h. Long‐term storage freeze/thaw and
bench‐top stabilities were determined at LQC and HQC. Long‐term
storage stability in processed biomatrix was tested up to 40 days upon
storage at −80°C. Bench‐top stability was evaluated from samples kept
at room temperature for 15 h before extraction. Freeze/thaw stability
was tested over five cycles of freezing and thawing.
2.10 | Application to real samples
Tumor‐bearing BALB/c mice were anesthetized and injected into the
lateral tail vein with DOX, free or encapsulated in ferritin nanoparticles
(HFer‐DOX) or in liposomes (CAELYX) (1.24mg kg−1; n = 24 mice/
group). One, 2, 24 and 48 h after injection mice were killed (n = 6 miceTA
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per group) and plasma, liver, kidneys and urine were collected. Organs
were collected, weighted, homogenized in waterQ11 (10% w/v) with potterQ12
(Glas‐Col homogenizer), as described above. Mice were used in accor-
dance with an experimental protocol subjected to the direct approval
of the Italian Ministry of Health. Aliquots of samples were extracted,
analyzed, and DOX and DOXol quantified to investigate the
biodistribution of DOX and DOXol, associated to the three different
formulations. Results obtained are reported in FiguresF2 2F3F4 –4.
2.11 | Statistics
If not otherwise specified, quantitative analyses were performed in
triplicate. Calibration curves are expressed as mean ± SD. For applica-
tion to real samples, six mice per group were analyzed and each matrix
was extracted and analyzed in triplicate. Reported data are expressed
as the mean of all analyses performed per group ± SD.
3 | RESULTS AND DISCUSSION
The reflection that the reduction of DOX to DOXol involves the addi-
tion of only two mass units emphasizes the need for adequate
methods for their quantification. There are several analytical methods,
including HPLC‐MS/MSmethods, available for DOX and DOXol deter-
mination (Ahmed et al., 2009; Ibsen et al., 2013; Lachâtrea et al., 2000;
Liu et al., 2008; Ricciarello et al., 1998; Sottani et al., 2013; Zhou &
Chowbay, 2002). However, most of them have disadvantages, such
as long analytical run time (16min; Sottani et al., 2013) or (21min;
Ibsen et al., 2013), or complex and expensive extraction procedures,
solid phase extraction procedure on expensive OASIS HBLQ13 (Ibsen
et al., 2013; Lachâtrea et al., 2000; Liu et al., 2008; Sottani et al.,
2013). Moreover, the majority of published methods are focused on
quantifications of DOX and some of its metabolites in plasma matrix
using at least 100 μL of the sample (Lachâtrea et al., 2000; Liu et al.,
2008; Sottani et al., 2013), but unfortunately these quantities are too
large for the application in pharmacological studies on mouse models.
To date, less attention was paid to the analysis of DOX and its
metabolite DOXol in mouse tissue samples (Arnold et al., 2004; Cao
& Bae, 2012; Park et al., 2006). In this study, we developed and vali-
dated an LC‐MS/MS method for simultaneous determination of DOX
and DOXol in small amounts of plasma, urine, liver, kidneys and tumor
tissue suitable to study the distribution profile of these molecules in
the organism after DOX administration. This method will be a powerful
tool for drug distribution evaluation in pharmaceutical research to
understand better the side effect mechanisms linked to DOX
administration.
We selected DAU as internal standard for quantification because
it is an analog of DOX with chemical and structural characteristics suit-
able for this purpose. The use of DAU as the internal standard for DOX
and DOXol quantification, indeed, is well documented in the literature
(Maudens, Stove, & Lambert, 2011). Moreover the choice of DAU, less
expensive and readily commercially available, instead of the deute-
rium‐labeled DOX makes the method cheap and easily applicable, suit-
able for pharmacological research but also attractive for drug
monitoring. The validation fully performed in the five biomatrices
probably helps to overcome possible problems linked to the choice
of the internal standard.
The present method, with high sensitivity and specificity, proposes
a simple, fast and cheap LLE applicable to a large number of
biomatrices. Indeed, the method has been validated on five different
biomatrices such as plasma, urine and three different kind of tissues
comprising liver, kidneys and tumor tissue, which is more difficult to
homogenize and extract due to its fibrous characteristic. Moreover,
DOX and DOXol quantification in samples from mice treated with free
DOX, CAELYX or HFer‐DOX, have been used as a preliminary study to
investigate their biodistribution profiles to evaluate the differences
associated to the nano‐formulations, demonstrated the applicability
of the method to real samples (Figures 2 and 3).
3.1 | Extraction procedure and analytic conditions
LLE was examined using different organic solvents such as dichloro-
methane, ethyl acetate, chloroform, hexane and isopropyl alcohol with
different acidic and basic aqueous solutions.
TABLE 4 Intra‐ and interday precision (%CV) and accuracy (%RSE) of DOX and DOXol
(%CV) intraday (%CV) interday (%RSE) intraday (%RSE) inter‐day
LQC MQC HQC LQC MQC HQC LQC MQC HQC LQC MQC HQC
DOX
Plasma 2.5 3.8 5.6 4.2 6.3 5.7 5.1 6.6 6.2 9.5 10.1 9.7
Liver 3.6 4.6 5.3 5.3 4.5 8.8 10.6 6.0 5.6 9.6 11.3 8.9
Kidney 4.1 5.4 3.9 5.7 6.6 7.3 4.5 8.3 9.9 12.2 9.5 9.5
Tumor 7.2 5.2 4.1 3.9 5.4 8.6 10.2 9.6 7.7 12.9 9.3 8.2
Urine 3.3 4.7 4.5 5.9 6.7 5.5 6.9 5.4 4.7 8.6 7.1 5.9
DOXol
Plasma 3.5 5.2 2.7 3.2 5.5 8.0 7.2 6.1 9.6 9.1 9.7 5.9
Liver 4.3 2.6 5.1 8.9 3.7 5.6 4.5 9.0 5.6 10.2 6.6 10.6
Kidney 4.2 4.3 5.9 7.0 6.4 8.1 5.3 4.8 8.6 11.9 7.3 6.2
Tumor 3.6 4.5 4.8 7.6 5.9 4.2 12.7 10.9 4.9 14.7 13.8 8.3
Urine 4.5 3.8 6.1 3.2 4.6 9.3 6.9 3.8 10.2 8.8 7.1 4.6
CV, coefficient of variance; DOX, doxorubicin; DOXol, doxorubicinol; HQC, high quality control; LQC, low quality control; MQC, medium quality control;
RSE, relative standard error.
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The protocol where the acidic dilution of the sample (H2SO4 1mM
in water) was combined with chloroform/isopropyl alcohol (50: 50 v/v)
was found to provide very good extraction yields of the two
compounds (i.e. DOX and DOXol) displaying a clean chromatogram.
Furthermore, the same LLE method can be applied to a large number
of different biomatrices as plasma and urine and different tissues such
as liver, kidney and tumor with good results in terms of recovery and
chromatogram quality. Direct extraction with organic solvent, indeed,
gave worst chromatograms leading to less sensibility. At the same time,
the pre‐dilution with sodium borate solution or acetate or KOH gave a
substantial decrease in recovery. Moreover, the selected extraction is
fast and cheap allowing easy management of a large number of
samples, as generally happens in therapeutic drug monitoring.
3.2 | HPLC‐MS/MS analysis
The development of the HPLC‐MS/MS method started with optimiza-
tion ofMS ionization and fragmentation of both the analytes and internal
standard (DOX, DOXol and DAU; each 100 ng/mL) via infusion into the
electrospray source in positive and negative ionization mode. A positive
ionization mode exhibited a better response than that in negative mode.
The protonated precursor ionsm/z 544.2 [M+H]+, 546.2 [M+H]+
and 528.2 [M +H]+ generated product ions m/z 397.5, 361.5, 355.5
and 130.0, 399.5, 363.5 and 130.0, 363.5 and 321.5, by collision‐
induced dissociation for DOX, DOXol and DAU, respectively (Table 1).
Using multiple reaction monitoring analyses collision energy was
varied from 0 to 60 eV and adjusted for DOX, DOXol and DAU to
maximize product ion formation of transitions selected for quantifica-
tion (m/z 397.5 and 361.5 for DOX, 399.5 and 363.5 for DOXol, and
363.5 for DAU). Figure 1 reported MS/MS spectra of analytes along
with the chromatographic separation of DOX DOXol and DAU in a
mouse plasma sample. The obtained chromatographic separation
was satisfactory between DOX, DOXol and DAU using a short run
time Q14and the use of an MS/MS technique on a triple quadrupole,
with an m/z interval of 0.5 on the first quadrupole, which meant it
was possible to overcome the possible loss in accuracy due to the
selection of the product ion m/z 363.5 for quantification of both
DOXol and DAU. Therefore, various mobile phase compositions with
a different pH value, column and flow rate were tried. Reverse phase
HPLC column exhibited best sensitivity, efficiency and peak shape
with a gradient of acetonitrile and ammonium formate 10mM (0.1%
formic acid) as mobile phases, at a flow rate of 0.35mL/min. The
FIGURE 3 DOX and DOXol accumulation at 4 T1‐L tumor in mice at
different time points after administration of 1.24mg/kg of free DOX
(black), CAELYX (white) and HFer‐DOX (gray). Female BALB/c mice
orthotopically implanted with 4 T1‐L murine mammary carcinoma cells
were injected 6 days after implantation (time 0) with DOX or HFn‐
DOX. DOX levels in tumors have been determined 1, 2, 24 and 48 h
after intravenous injection following acidified isopropanol extraction
from tumor homogenates. Aliquots from six mice per each time point
concentration have been extracted in duplicate and analyzed by
HPLC/MS/MS. Reported values are means of six samples/group in
duplicate ± SE. DOX, doxorubicin; DOXol, doxorubicinol
FIGURE 2 Bioavailability of free DOX in comparison with liposomal
(CAELYX) and ferritin nano‐formulated DOX (HFer‐DOX) at different
time points. Female BALB/c mice orthotopically implanted with 4 T1‐L
murinemammary carcinoma cells were injected 6 days after implantation
(time 0) with free DOX (black), CAELYX (white) and HFer‐DOX (gray)
1.24mg/kg. DOX andDOXol levels in plasma have been determined 1, 2,
24 and 48h after intravenous injection following acidified isopropanol
extraction from tumor homogenates. Aliquots from six mice per each
time point concentration have been extracted in duplicate and analyzed
by HPLC/MS/MS. Reported values are means of six samples/group in
duplicate ± SE. DOX, doxorubicin; DOXol, doxorubicinol
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retention times of both the analytes (DOX 4.49min and DOXol
4.43min) and DAU (4.54min) were low enough to allow a short total
run time of 8.0min comprising clearing and reconditioning of the col-
umn with the initial mobile phase.
3.3 | Validation
The assay was fully validated following the acceptance criteria of the
US Food and Drug Administration guidelines to demonstrate the line-
arity, precision, accuracy, limits of the methods LOQ and LODQ15 , recov-
ery and sample stability by using the CS and QC samples prepared in all
five biomatrices.
3.4 | Selectivity, carry‐over and sensitivity
The selection of a specific precursor ion followed by the formation
and detection of a specific product ion makes quantitative MS highly
specific. All reagents and disposable materials used did not interfere
with the revelation and quantification of DOX and DOXol. Biological
matrices did not give false positive responses or co‐eluting compo-
nents. No carry‐over to analytes from one sample to another was
observed.
LOD and LOQ levels have been calculated for plasma, urine and
tissues as reported in the experimental part and are listed in Table 1.
The LOD range from 0.025 to 0.52 ng/mL for DOX and 0.09 to
0.35 ng/mL for DOXol, and the LOQ range from 0.08 to 1.73 ng/mL
for DOX and 0.32 to 1.17 ng/mL for DOXol. All the assay values were
found to be within the accepted variable limits (±15% RSE, ≤15% CV
and ±20% RSE, ≤20% CV) (Morin, Taillon, Furtado, & Garafolo,
2012). The differences between LOD and LOQ values reflect the dif-
ferent complexity of the five matrices. LOD and LOQ values indeed
increase with the complexity of matrices from urine to tumor tissue.
Despite these differences, the method display a good sensitivity in all
assessed matrices.
FIGURE 4 Biodistribution of DOX and DOXol upon single administration of 1.24mg/kg of free DOX (black), CAELYX (white) and HFer‐DOX
(gray). Tumor‐bearing mice (n = 24/group) were treated with HFn‐DOX or free DOX. Liver, kidneys and urine were collected at 1, 2, 24 and
48 h after injection. DOX and DOXol content in each sample were analyzed by HPLC/MS/MS. Reported values are means of six samples/group in
duplicate ± SE. DOX, doxorubicin; DOXol, doxorubicinol
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3.5 | Linearity, accuracy and precision
Linear calibration curves, built according to the formula y =mx + b,
were obtained by plotting the peak area ratio of internal standard ver-
sus concentrations of DOX and DOXol. Good linearity (r > 0.99) was
exhibited over concentration range of 5–250 ng/mL for DOX and
1.25–25 ng/mL for DOXol in plasma and tumor, 25–500 ng/mL for
DOX and 1.25–25 ng/mL for DOXol in kidney and liver, and of
25–1000 ng/mL for DOX and DOXol in urine (Table 3). These different
ranges were selected for the assessed biomatrices to have good cali-
bration curves, for the expected values, useful for DOX and DOXol
quantification in real samples from in vivo studies.
Accuracy and precision were assessed by analyzing QC on three
different days. Results can be summarized as follows: intraday preci-
sion ranges are 2.5–7.2% for DOX and 2.7–6.1% for DOXol, interday
3.9–8.8% for DOX and 3.2–9.3% for DOXol, intraday and interday
accuracy range 4.5–10.2% for DOX and 3.8–12.7% for DOXol and
5.9–12.9% for DOX and 4.6–14.7% for DOXol respectively (Table 4).
Results reported in Table 4 show that interday accuracy in tumor
tissue present highest values of %RSE that are within the accepted
limit of 15%.
3.6 | Recovery and matrix effect
The recovery has been evaluated by the post‐extraction method. The
mean extraction recovery ratios of DOX and DOXol of QCs are
between 58 and 96% and between 47 and 85% respectively.
(3.2 ≥CV ≤ 8.6).
Matrix effects are reported in Table 4 with recoveries and
expressed as the ion suppression percentage that ranges 1–38% for
DOX and 10–32% for DOXol (2.9 ≥CV ≤ 10.3). As LOD and LOQ even
recovery and matrix effect values reflect increasing complexity from
urine to tissues.Q16
3.7 | Sample stability
Stability of DOX and DOXol in biomatrices was evaluated under a vari-
ety of conditions to establish length of storage and sample processing.
DOX and DOXol exhibited no significant degradation under previously
described conditions. In particular, analytes are stable in biomatrices
for 15 h at room temperature, five freeze–thaw cycles and for 3 days
at room temperature (processed samples). Stock solutions are stable
at least for 1month at −80°C.
3.8 | Application of the method
This method has been applied to study the impact of nano‐formulation
on DOX and DOXol biodistribution. As nano‐formulated drugs, we
have selected CAELYX and HFer‐DOX. The first is a liposomal
DOX currently applied in clinical practice, while the last is a very
promising nano‐formulation of DOX, which until now was investi-
gated in pre‐clinical studies. While CAELYX mediates the DOX
tumor delivery taking advantage of the enhanced permeability and
retention effect, HFer‐DOX triggered a tumor‐targeted nuclear deliv-
ery of drug (Barenholz, 2012; Bellini et al., 2014; Zhang et al., 2015).
Tumor‐bearing BALB/c mice were treated with free DOX, CAELYX
or HFer‐DOX (1.24mg DOX kg−1). One, 2, 24 and 48 h after
intravenous injection into the tail vein, mice (n = 6/experimental
group) were killed and plasma, urine, tumor, liver and kidneys were
collected. DOX and DOXol were extracted from biological samples
and analyzed. Where necessary, plasma of CAELYX‐treated mice
and urine of HFer‐DOX‐treated mice were diluted with water
(HPLC purity grade) before extraction to obtain concentration
included in the linearity range. Liposomal nano‐formulation of DOX
(i.e. CAELYX) significantly improves drug bioavailability and circula-
tion time in comparison to free DOX and HFer‐DOX samples.
However, liposomal nano‐formulation fails in avoiding the DOX
transformation into DOXol, increasing also DOXol bioavailability
and circulation time, which may result in high drug toxicity (Figure 2).
Time‐dependent DOX and DOXol tumor accumulation reported in
Figure 3 clearly points out that DOX and HFer‐DOX come to tumor
quickly reaching the maximum value of drug content between 1 and
2 h after injection, while CAELYX arrives to cancer slowly, achieving
the peak value 24 h after nanoparticle administration. DOXol
accumulation sketchily follows that observed for the profile of
DOX, except for the significant contribution of ferritin nanocage/
nano‐formulation to enhance tumor accumulation of DOXol in
comparison to the free drug. In contrast to tumor samples, both
DOX and DOXol showed higher accumulation in off‐target organs
in DOX‐treated mice, suggesting a role of nano‐formulation in
reducing the capture of DOX and metabolites from liver and kidneys,
which may result in lower toxicity (Figure 4). Moreover, urine samples
strongly evidenced that the faster tumor accumulation and the short
circulation time observed in free DOX and HFer‐DOX samples are
coupled with a faster washout, which may affect the drug therapeutic
index (Figure 4).
4 | CONCLUSIONS
In conclusion, a selective, sensitive and rapid LC‐MS/MS method
was developed and validated to determine simultaneously the
concentration of DOX and its reduced metabolite DOXol in small
volumes of murine plasma, urine and tissue samples. An excellent
linearity (R2 > 0.99), good accuracy, precision and specificity meet-
ing acceptability criteria according to US Food and Drug Adminis-
tration guidelines have been demonstrated for the determination
of DOX and its 13‐hydroxy metabolite, using DAU as the internal
standard. Moreover, the simple, quick and cheap extraction proce-
dure, applicable to a large number of biomatrices, and the short
chromatographic run time, together with the requirements of very
low plasma, urine or tissue samples, render this method particularly
attractive for pharmacological research performed on murine animal
models. Finally, this method has been applied to measure the
biodistribution of DOX and DOXol in the mouse organism after
administration of nanoparticles carrying DOX as an antitumor
agent, demonstrating it as a powerful tool for pharmaceutical
research.
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of answers to queries by entering your answers on the query sheet, in addition to the text mark-up.
Query No. Query Remark
Q1 AUTHOR: Please confirm that given names (red) and surnames/family names (green)
have been identified correctly.
Q2 AUTHOR: The citation “Duggan et al., 2011” has been changed to “Duggan and
Keating, 2011” to match the author name/date in the reference list. Please check if
the change is fine in this occurrence and modify the subsequent occurrences, if
necessary.
Q3 AUTHOR: The citation “Zhou et al., 2002” has been changed to “Zhou and Chowbay,
2002” to match the author name/date in the reference list. Please check if the change is
fine in this occurrence and modify the subsequent occurrences, if necessary.
Q4 AUTHOR: The citation “Cao et al., 2012” has been changed to “Cao and Bae, 2012” to
match the author name/date in the reference list. Please check if the change is fine in this
occurrence and modify the subsequent occurrences, if necessary.
Q5 AUTHOR: PerkinElmer—pls add address
Q6 AUTHOR: potter—what is this?
Q7 AUTHOR: All CS and QC samples—OK now (was 'All CS and QS samples')?
Q8 AUTHOR: The citation “US Department of Health and Human Services, 2001” has
been changed to “US Department of Health and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research, CDER, 2001” to match the
author name/date in the reference list. Please check if the change is fine in this
occurrence and modify the subsequent occurrences, if necessary.
Q9 AUTHOR: To exclude any interference or false positive response derived from
extractive procedure, reagents or disposable, blank water was extracted according to
the method—is this the method described above?
Q10 AUTHOR: to yield post‐extraction samples containing DOX and DOXol at 5–25 and
100ng/mL and 1.25–5 and 25 ng/mL respectively—OK or should this be 'to yield
post‐extraction samples containing DOX and DOXol at 5, 25 and 100 ng/mL and
1.25, 5 and 25 ng/mL respectively'?
Q11 AUTHOR: Organs were collected, weighted, homogenized in water—OK or should
'weighted' be 'weighed' here?
Q12 AUTHOR: potter—what is this?
Query No. Query Remark
Q13 AUTHOR: OASIS HBL—what is this?
Q14 AUTHOR: The obtained chromatographic separation was satisfactory between DOX,
DOXol and DAU using a short run time—OK now?
Q15 AUTHOR: limits of the methods LOQ and LOD—does this make sense? Should it just
be 'LOQ and LOD methods'?
Q16 AUTHOR: As LOD and LOQ even recovery and matrix effect values reflect increasing
complexity from urine to tissues.—does this make sense?
Q17 AUTHOR: Figure 1 contains poor quality of text. Please resupply if necessary.
 
USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION  
 
Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 7.0 or 
above). (Note that this document uses screenshots from Adobe Reader X) 
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/uk/reader/ 
 
Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Replace (Ins) Tool – for replacing text. 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
How to use it 
 Highlight a word or sentence. 
 Click on the Replace (Ins) icon in the Annotations 
section. 
 Type the replacement text into the blue box that 
appears. 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
pictured opposite. We’ve picked out some of these tools below: 
2. Strikethrough (Del) Tool – for deleting text. 
 
Strikes a red line through text that is to be 
deleted. 
How to use it 
 Highlight a word or sentence. 
 Click on the Strikethrough (Del) icon in the 
Annotations section. 
 
 
3. Add note to text Tool – for highlighting a section 
to be changed to bold or italic. 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
How to use it 
 Highlight the relevant section of text. 
 Click on the Add note to text icon in the 
Annotations section. 
 Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool – for making notes at 
specific points in the text. 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
How to use it 
 Click on the Add sticky note icon in the 
Annotations section. 
 Click at the point in the proof where the comment 
should be inserted. 
 Type the comment into the yellow box that 
appears. 
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For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool – for inserting large amounts of 
text or replacement figures. 
 
Inserts an icon linking to the attached file in the 
appropriate pace in the text. 
How to use it 
 Click on the Attach File icon in the Annotations 
section. 
 Click on the proof to where you’d like the attached 
file to be linked. 
 Select the file to be attached from your computer 
or network. 
 Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Add stamp Tool – for approving a proof if no 
corrections are required. 
 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it 
 Click on the Add stamp icon in the Annotations 
section. 
 Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
 Click on the proof where you’d like the stamp to 
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools – for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
How to use it 
 Click on one of the shapes in the Drawing 
Markups section. 
 Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
 To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
 Double click on the shape and type any 
text in the red box that appears. 
